| Clinical application of monoclonal antibody-drug conjugate to immunotargeting chemotherapy of bladder cancer. |
| |
| 作者姓名： | 李龙承 章咏裳 林乔 李川江 何敏 |
| |
| 作者单位： | Department of Urology Tongji Hospital.Tonji Medical University，Wuhan430030，Department of Urology，Tongji Hospital.Tonji Medical University，Wuhan430030，Institute of Virus Research，Hubei Academy of Medical Sciences，Wuhan 430070，Institute of Virus Research，Hubei Academy of Medical Sciences，Wuhan 430070，Institute of Virus Research，Hubei Academy of Medical Sciences，Wuhan 430070 |
| |
| 基金项目： | This study was supported by a grant from the National Natural Science Foundation of China. |
| |
| 摘 要： | Monocional antibody-drug conjugate was applied in a clinical trial for patients with bladder cancer.Monoclonal antibody HB7A from a mouse splenocyte immunized against human bladder cancer was used as a drug carrier.The anti-cancer drug adriamycin(ADR) was bound to HB7A through a dextran(DEX) bridge to form the conjugate HB7A-DEX-ADR. The in vitro cytotoxic effect of the conjugate on BIU-87 bladder cancer cells was similar to that of free ADR and the mixture of HB7A and ADR. Seven patients with bladder cancer were given HB7A-DEX-ADR intravenously.The immanoperoxidase studies of the resected specimens showed that HB7A was localized specifically in cancer, and histological studies revealed degenerative and necrotic changes of the tumor cells. Patients receiving the conjugate did not experience serious side effects. This study suggests that im munotargeting chemotherapy with HB7A-DEX-ADR is well tolerated by patients and its cytotoxicity on tumor is substanrial.
|
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《中华医学杂志(英文版)》浏览原始摘要信息 |
|
点击此处可从《中华医学杂志(英文版)》下载全文 |
